FCF Yield

The current FCF Yield of -7.3% means that for every dollar of stock price, the company is generating negative free cash flow—essentially burning cash relative to its market value.

This places CRISPR Therapeutics well below the healthcare sector median of 3.4%, ranking it in the 19th percentile among peers, indicating a much weaker cash-flow position than most comparable companies. Trend data is not available: year-over-year and quarter-over-quarter changes are both listed as N/A, so no directional pattern can be inferred from past periods. The combination of a deeply negative FCF yield with no observable trend suggests elevated cash-burn risk, but without historical context it is unclear whether this is improving or worsening. This metric contradicts a positive investment outlook but does not alone justify a bearish stance, as biotech companies often have negative cash flow during development phases. Given the NEUTRAL verdict, the negative FCF yield reinforces the lack of a clear catalyst for upside, supporting a cautious hold rather than a buy or sell.

Frequently Asked Questions

Closest Sector Peers